BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 20718834)

  • 21. The expression and prognostic significance of bcl-2-associated transcription factor 1 in rectal cancer following neoadjuvant therapy.
    Brown GT; Cash B; Alnabulsi A; Samuel LM; Murray GI
    Histopathology; 2016 Mar; 68(4):556-66. PubMed ID: 26183150
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictive immunohistochemical features for tumour response to chemoradiotherapy in rectal cancer.
    Shinto E; Omata J; Sikina A; Sekizawa A; Kajiwara Y; Hayashi K; Hashiguchi Y; Hase K; Ueno H
    BJS Open; 2020 Apr; 4(2):301-309. PubMed ID: 32026629
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ALDH1 is a prognostic factor for patients treated with neoadjuvant chemoradiotherapy and radical resection for stage III rectal cancer.
    Oh SY; Sohn SH; Yim H; Lee D; Suh KW; Kim YB
    J Surg Oncol; 2015 Feb; 111(2):243-7. PubMed ID: 25270363
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of tumour regression grade in locally advanced rectal cancer: a systematic review and meta-analysis.
    Kong JC; Guerra GR; Warrier SK; Lynch AC; Michael M; Ngan SY; Phillips W; Ramsay G; Heriot AG
    Colorectal Dis; 2018 Jul; 20(7):574-585. PubMed ID: 29582537
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rsf-1 expression in rectal cancer: with special emphasis on the independent prognostic value after neoadjuvant chemoradiation.
    Lin CY; Tian YF; Wu LC; Chen LT; Lin LC; Hsing CH; Lee SW; Sheu MJ; Lee HH; Wang YH; Shiue YL; Wu WR; Huang HY; Hsu HP; Li CF; Chen SH
    J Clin Pathol; 2012 Aug; 65(8):687-92. PubMed ID: 22569540
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Hypoxia-inducible factor-1α and CD133 predicts pathological complete response and survival for locally advanced rectal cancer patients after neoadjuvant chemoradiotherapy].
    Cai C; Wang J; Zhong Z; Dai Z; Wang Q; Dong W; Shi H; Liu Q; DU J
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2017 Jan; 46(1):36-43. PubMed ID: 28436629
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pretreatment CD133 and cyclooxygenase-2 expression as the predictive markers of the pathological effect of chemoradiotherapy in rectal cancer patients.
    Shinto E; Hashiguchi Y; Ueno H; Kobayashi H; Ishiguro M; Mochizuki H; Yamamoto J; Hase K
    Dis Colon Rectum; 2011 Sep; 54(9):1098-106. PubMed ID: 21825889
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictive markers of chemoradiotherapy for rectal cancer: comparison of biopsy specimens taken before and about 1 week after the start of chemoradiotherapy.
    Suzuki T; Sadahiro S; Tanaka A; Okada K; Saito G; Kamijo A; Akiba T; Kawada S
    Int J Clin Oncol; 2015 Dec; 20(6):1130-9. PubMed ID: 25833701
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fibroblast growth factor receptor 2 overexpression is predictive of poor prognosis in rectal cancer patients receiving neoadjuvant chemoradiotherapy.
    Li CF; He HL; Wang JY; Huang HY; Wu TF; Hsing CH; Lee SW; Lee HH; Fang JL; Huang WT; Chen SH
    J Clin Pathol; 2014 Dec; 67(12):1056-61. PubMed ID: 25271212
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gene expression profiles of epidermal growth factor receptor, vascular endothelial growth factor and hypoxia-inducible factor-1 with special reference to local responsiveness to neoadjuvant chemoradiotherapy and disease recurrence after rectal cancer surgery.
    Toiyama Y; Inoue Y; Saigusa S; Okugawa Y; Yokoe T; Tanaka K; Miki C; Kusunoki M
    Clin Oncol (R Coll Radiol); 2010 May; 22(4):272-80. PubMed ID: 20117921
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic significance of tumor regression in lymph nodes after neoadjuvant therapy for rectal carcinoma.
    Fernández-Aceñero MJ; Granja M; Sastre J; García-Paredes B; Estrada L
    Virchows Arch; 2016 Apr; 468(4):425-30. PubMed ID: 26754675
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Importance of tumor regression assessment in predicting the outcome in patients with locally advanced rectal carcinoma who are treated with preoperative radiotherapy.
    Bouzourene H; Bosman FT; Seelentag W; Matter M; Coucke P
    Cancer; 2002 Feb; 94(4):1121-30. PubMed ID: 11920483
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinicopathological significance and prognostic value of CD133 expression in triple-negative breast carcinoma.
    Zhao P; Lu Y; Jiang X; Li X
    Cancer Sci; 2011 May; 102(5):1107-11. PubMed ID: 21276138
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor Regression Grading After Preoperative Chemoradiotherapy as a Prognostic Factor and Individual-Level Surrogate for Disease-Free Survival in Rectal Cancer.
    Fokas E; Ströbel P; Fietkau R; Ghadimi M; Liersch T; Grabenbauer GG; Hartmann A; Kaufmann M; Sauer R; Graeven U; Hoffmanns H; Raab HR; Hothorn T; Wittekind C; Rödel C;
    J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29206996
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term prognostic value of mesorectal grading after neoadjuvant chemoradiotherapy for rectal cancer.
    Madbouly KM; Hussein AM; Abdelzaher E
    Am J Surg; 2014 Sep; 208(3):332-41. PubMed ID: 24581995
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diffuse myogenin expression by immunohistochemistry is an independent marker of poor survival in pediatric rhabdomyosarcoma: a tissue microarray study of 71 primary tumors including correlation with molecular phenotype.
    Heerema-McKenney A; Wijnaendts LC; Pulliam JF; Lopez-Terrada D; McKenney JK; Zhu S; Montgomery K; Mitchell J; Marinelli RJ; Hart AA; van de Rijn M; Linn SC
    Am J Surg Pathol; 2008 Oct; 32(10):1513-22. PubMed ID: 18708938
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunohistochemical features of CD133 expression: association with resistance to chemoradiotherapy in rectal cancer.
    Saigusa S; Tanaka K; Toiyama Y; Yokoe T; Okugawa Y; Kawamoto A; Yasuda H; Morimoto Y; Fujikawa H; Inoue Y; Miki C; Kusunoki M
    Oncol Rep; 2010 Aug; 24(2):345-50. PubMed ID: 20596619
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of COX-2 and Ki-67 over-expression in the prediction of pathologic response of rectal cancer to neoadjuvant chemoradiation therapy.
    Jafarian AH; Kermani AT; Esmaeili J; Roshan NM; Seilanian-Toosi M; Omidi AA; Shahri MK
    Indian J Cancer; 2016; 53(4):548-551. PubMed ID: 28485348
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical significance of CD133 and hypoxia inducible factor-1α gene expression in rectal cancer after preoperative chemoradiotherapy.
    Saigusa S; Tanaka K; Toiyama Y; Yokoe T; Okugawa Y; Koike Y; Fujikawa H; Inoue Y; Miki C; Kusunoki M
    Clin Oncol (R Coll Radiol); 2011 Jun; 23(5):323-32. PubMed ID: 20970309
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Do pathological variables have prognostic significance in rectal adenocarcinoma treated with neoadjuvant chemoradiotherapy and surgery?
    Reggiani Bonetti L; Lionti S; Domati F; Barresi V
    World J Gastroenterol; 2017 Feb; 23(8):1412-1423. PubMed ID: 28293088
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.